Found: 160
Select item for more details and to access through your institution.
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.
- Published in:
- 2011
- By:
- Publication type:
- journal article
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1324, doi. 10.1007/s10637-021-01104-7
- By:
- Publication type:
- Article
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 6, p. 1246, doi. 10.1007/s10637-014-0151-0
- By:
- Publication type:
- Article
Piwi-Interacting RNAs (piRNAs) Are Dysregulated in Renal Cell Carcinoma and Associated with Tumor Metastasis and Cancer-Specific Survival.
- Published in:
- Molecular Medicine, 2015, v. 21, n. 1, p. 381, doi. 10.2119/molmed.2014.00203
- By:
- Publication type:
- Article
Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
- Published in:
- BJU International, 2020, v. 126, n. 1, p. 73, doi. 10.1111/bju.15058
- By:
- Publication type:
- Article
Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.
- Published in:
- BJU International, 2020, v. 125, n. 5, p. 739, doi. 10.1111/bju.15006
- By:
- Publication type:
- Article
Non‐invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?
- Published in:
- BJU International, 2019, v. 124, n. 3, p. 361, doi. 10.1111/bju.14877
- By:
- Publication type:
- Article
Distress in patients with renal cell carcinoma: a curious gap in knowledge.
- Published in:
- BJU International, 2019, v. 123, n. 2, p. 208, doi. 10.1111/bju.14564
- By:
- Publication type:
- Article
Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the CHAARTED trial.
- Published in:
- 2015
- By:
- Publication type:
- Editorial
Geography: an increasingly important variable in prostate cancer clinical trials.
- Published in:
- 2015
- By:
- Publication type:
- Editorial
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy.
- Published in:
- Nutrients, 2024, v. 16, n. 11, p. 1630, doi. 10.3390/nu16111630
- By:
- Publication type:
- Article
Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.
- Published in:
- PLoS ONE, 2019, v. 14, n. 1, p. 1, doi. 10.1371/journal.pone.0210415
- By:
- Publication type:
- Article
Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.
- Published in:
- Journal of Genetic Counseling, 2024, v. 33, n. 4, p. 911, doi. 10.1002/jgc4.1786
- By:
- Publication type:
- Article
Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 8, p. e2425288, doi. 10.1001/jamanetworkopen.2024.25288
- By:
- Publication type:
- Article
Barriers to Clinical Trial Implementation Among Community Care Centers.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 4, p. e248739, doi. 10.1001/jamanetworkopen.2024.8739
- By:
- Publication type:
- Article
Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation.
- Published in:
- Case Reports in Oncology, 2020, v. 13, n. 1, p. 456, doi. 10.1159/000506625
- By:
- Publication type:
- Article
Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma.
- Published in:
- Case Reports in Oncology, 2018, v. 11, n. 2, p. 276, doi. 10.1159/000489995
- By:
- Publication type:
- Article
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response.
- Published in:
- AUANews, 2023, p. 23
- By:
- Publication type:
- Article
Biopsychosocial distress and clinical outcome in metastatic renal cell carcinoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 8, p. 1831, doi. 10.3390/ijms20081831
- By:
- Publication type:
- Article
The role of peroxisome proliferator-activated receptor gamma in prostate cancer.
- Published in:
- Asian Journal of Andrology, 2018, v. 20, n. 3, p. 1, doi. 10.4103/aja.aja_15_17
- By:
- Publication type:
- Article
Management of localized prostate cancer: the pendulum swings (back to the middle).
- Published in:
- Asian Journal of Andrology, 2014, v. 16, n. 4, p. 570, doi. 10.4103/1008-682X.131072
- By:
- Publication type:
- Article
Radium-223 in metastatic castration resistant prostate cancer.
- Published in:
- Asian Journal of Andrology, 2014, v. 16, n. 3, p. 348, doi. 10.4103/1008-682X.127812
- By:
- Publication type:
- Article
Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer.
- Published in:
- Asian Journal of Andrology, 2011, v. 13, n. 5, p. 683, doi. 10.1038/aja.2011.35
- By:
- Publication type:
- Article
Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors.
- Published in:
- Journal of Oncology Pharmacy Practice, 2018, v. 24, n. 3, p. 190, doi. 10.1177/1078155217693426
- By:
- Publication type:
- Article
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma.
- Published in:
- Clinical & Translational Medicine, 2022, v. 12, n. 7, p. 1, doi. 10.1002/ctm2.948
- By:
- Publication type:
- Article
Tuberculosis of Distal Radius Presenting as Cystic Lesion in a Nine-Month-Old Infant: A Rare Case Report.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
Activin Receptor Inhibitors-Dalantercept.
- Published in:
- Current Oncology Reports, 2015, v. 17, n. 4, p. 1, doi. 10.1007/s11912-015-0441-5
- By:
- Publication type:
- Article
Factors that influence the androgen receptor cistrome in benign and malignant prostate cells.
- Published in:
- Molecular Oncology, 2019, v. 13, n. 12, p. 2616, doi. 10.1002/1878-0261.12572
- By:
- Publication type:
- Article
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
- Published in:
- Oncologist, 2024, v. 29, n. 3, p. 254, doi. 10.1093/oncolo/oyad348
- By:
- Publication type:
- Article
The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023.
- Published in:
- Oncologist, 2024, v. 29, n. 2, p. 91, doi. 10.1093/oncolo/oyad322
- By:
- Publication type:
- Article
Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.
- Published in:
- Oncologist, 2023, v. 28, n. 12, p. 1079, doi. 10.1093/oncolo/oyad190
- By:
- Publication type:
- Article
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
- Published in:
- Oncologist, 2023, v. 28, n. 10, p. 894, doi. 10.1093/oncolo/oyad132
- By:
- Publication type:
- Article
CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC).
- Published in:
- Oncologist, 2023, v. 28, p. S15, doi. 10.1093/oncolo/oyad216.025
- By:
- Publication type:
- Article
OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC).
- Published in:
- Oncologist, 2023, v. 28, p. S14, doi. 10.1093/oncolo/oyad216.023
- By:
- Publication type:
- Article
Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations.
- Published in:
- Oncologist, 2023, v. 28, p. S9, doi. 10.1093/oncolo/oyad216.014
- By:
- Publication type:
- Article
The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
- Published in:
- Oncologist, 2023, v. 28, p. S5, doi. 10.1093/oncolo/oyad216.008
- By:
- Publication type:
- Article
A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy.
- Published in:
- Oncologist, 2023, v. 28, n. 8, p. 699, doi. 10.1093/oncolo/oyad036
- By:
- Publication type:
- Article
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
- Published in:
- Oncologist, 2023, v. 28, n. 6, p. 494, doi. 10.1093/oncolo/oyad028
- By:
- Publication type:
- Article
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3.
- Published in:
- Oncologist, 2023, v. 28, n. 3, p. e167, doi. 10.1093/oncolo/oyac255
- By:
- Publication type:
- Article
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
- Published in:
- Oncologist, 2023, v. 28, n. 1, p. 59, doi. 10.1093/oncolo/oyac142
- By:
- Publication type:
- Article
Recall of Genomic Testing Results Among Patients with Cancer.
- Published in:
- Oncologist, 2021, v. 26, n. 12, p. e2302, doi. 10.1002/onco.13928
- By:
- Publication type:
- Article
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.
- Published in:
- Oncologist, 2021, v. 26, n. 12, p. 1026, doi. 10.1002/onco.13925
- By:
- Publication type:
- Article
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 560, doi. 10.1002/onco.13777
- By:
- Publication type:
- Article
Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.
- Published in:
- Oncologist, 2020, v. 25, n. 8, p. 680, doi. 10.1634/theoncologist.2019-0851
- By:
- Publication type:
- Article
Potential Roles for PD‐1 Inhibition and Cabozantinib in Patients with Metastatic Non‐Clear Cell Renal Cell Carcinoma.
- Published in:
- Oncologist, 2020, v. 25, n. 3, p. 186, doi. 10.1634/theoncologist.2019-0657
- By:
- Publication type:
- Article
The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
- Published in:
- Oncologist, 2020, v. 25, n. 1, p. e39, doi. 10.1634/theoncologist.2018-0528
- By:
- Publication type:
- Article
The Impact of Cisplatin‐ or Non‐Cisplatin‐Containing Chemotherapy on Long‐Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.
- Published in:
- Oncologist, 2019, v. 24, n. 10, p. 1348, doi. 10.1634/theoncologist.2018-0739
- By:
- Publication type:
- Article